---
title: Grant of share options
description: Moss, 02.08.18Reference is made to the stock exchange release of 14 May 2018 in which the Board of Directors decided to launch a share option programme of up to 559,852 options.
---

Moss, 02.08.18

Reference is made to the stock exchange release of 14 May 2018 in which the Board of Directors decided to launch a share option programme of up to 559,852 options. On 2 August 2018 the following employees was granted options in Gentian Diagnostics AS as follows:

Hilja Ibert, CEO of Gentian Diagnostics AS: 139,963 options. Number of options after the grant is 139,963 and number of shares are nil.

Njaal Kind, Group CFO of Gentian Diagnostics AS: 34,991 options. Number of options after the grant is 34,991 and number of shares are nil.

The exercise price for the options granted is NOK 65.24 being the average volume-weighted share price on the Oslo Stock Exchange for the past 10 trading days prior to today. The right to exercise the options is vested over a period of 3 years, with 1/3 of the options vesting by the end of each year as follows:

- 1/3 of the options granted, no earlier than 2 years after the allocation date
- 1/3 of the options granted, no earlier than 3 years after the allocation date
- 1/3 of the options granted, no earlier than 4 years after the allocation date

For further information, please contact: Tomas Settevik, Chairman Cell: +47 90 79 48 25

**MeldingsID:** 456430  
**UtstederID:** GENT-ME  
**Instrument:** GENT-ME  
**Marked:** Merkur Market  
**Kategori:** MELDEPLIKTIG HANDEL FOR PRIMÆRINNSIDERE  
**Informasjonspliktige opplysninger:** Ja

### You may also read

[Jul 02, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/grant-of-share-options#)

##### [Gentian Diagnostics: Invitation to presentation of second quarter results](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

Gentian Diagnostics ASA will present its second quarter 2026 results on 9 July 2026 at 09.00 CEST. The..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

[Jun 24, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/grant-of-share-options#)

##### [ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

Amsterdam / Moss, 24 June 2026 ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

[May 29, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/grant-of-share-options#)

##### [Mandatory notification of trade](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)

Moss, 29 May 2026 Gentian Diagnostics ASA ("Gentian") has today been notified that the following transaction..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)